Review board’s new reference countries have more limited access to new and innovative drugs.
The original OHIP+ provided limited coverage to a population that largely didn’t need assistance.
U.S. pharmaceutical innovation has been disproportionately funded by U.S. consumers of patented drugs.
In most countries with universal health care, patients share the cost of treatment—surgical or pharmaceutical.
Reform proposal misrepresents the nature of the global market and role of intellectual property.
National Pharmacare appears to be regarded by many as a panacea for the woes of the present hodgepodge of provincial drug plans, but some provinces seem to view it as an opportunity to alleviate the strain on their drug budgets.